Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PCIB.OL
- Price
- 1.33
- Stock movement up
- +0.01 (0.76%)
- Company name
- PCI Biotech Holding ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 49.64M
- Ent value
- -
- Price/Sales
- 30.95
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -15.00%
- 1 year return
- -22.31%
- 3 year return
- -31.29%
- 5 year return
- -49.38%
- 10 year return
- -16.17%
Last updated: 2025-04-12
DIVIDENDS
PCIB.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 30.95 |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 37.33M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.60M |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -19.77M |
| Net income (TTM) | -18.41M |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -1232.23% |
| Profit margin (TTM) | -1147.88% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 45.58M |
| Net receivables | 6.40M |
| Total current assets | 51.98M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 540.00K |
| Total assets | 52.52M |
| Accounts payable | 2.43M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 5.37M |
| Total liabilities | 5.61M |
| Shareholder's equity | 46.91M |
| Net tangible assets | 46.91M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.41M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -21.41M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.24 |
| Daily high | 1.33 |
| Daily low | 1.24 |
| Daily Volume | 46K |
| All-time high | 86.30 |
| 1y analyst estimate | 24.00 |
| Beta | 1.73 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PCIB.OL | S&P500 | |
| Current price drop from All-time high | -98.46% | -12.89% |
| Highest price drop | -98.62% | -56.47% |
| Date of highest drop | 30 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -61.13% | -11.07% |
| Avg time to new high | 96 days | 12 days |
| Max time to new high | 1561 days | 1805 days |
COMPANY DETAILS
Marketcap
49.64M
Marketcap category
Small-cap
Description
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. In addition, the company develops fimaVACC for immunotherapy indications, which is in pre-clinical study; fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study for bioprocessing and dermatology indications; and technology for viral vector manufacturing and pre-clinical research for intratumoural immunotherapy. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.
Employees
6
Website
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Oslo (Norway), 27 February 2025 – PCI Biotech (OSE: PCIB), today announces its preliminary full year 2024 results. Please find enclosed the interim report and presentation. Highlights review Operation...
February 27, 2025
Oslo, Norway, 25 February 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's full-year 2024 interim report on Thursday 27 February 2025, 08:30am – 09:00am CET (local tim...
February 25, 2025
Oslo, 10 January 2025 - PCI Biotech (OSE: PCIB), today announced that the Board of Directors has granted share options to Morten Luhr who has been promoted to Chief Scientific Officer (CSO) from Janua...
January 10, 2025
Oslo, 2 September 2024 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees. In accordance with the authorisation granted by the Annual Gene...
September 2, 2024
Oslo (Norway), 28 August 2024 – PCI Biotech (OSE: PCIB), today announces its interim first half 2024 results. Please find enclosed the interim report and presentation.Highlights review OperationsPCI B...
August 28, 2024
Oslo, Norway, 23 August 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2024 interim report on Wednesday 28 August 2024, 08:30am – 09:00am CEST (local time...
August 23, 2024
Oslo, 23 May 2024. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biote...
May 23, 2024
Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notic...
May 3, 2024